Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIP Study of rituximab, IVIG, and rescue plasmapheresis for desensitization before kidney transplantation
NL-OMON30466Phase 3Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab and immune globulin in end-stage kidney disease (ESKD), sponsored by Amsterdam University Medical Center. Primary endpoint: Achievement of a negative cross-match test with the donor kidney and transplantability. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
rituximabimmune globulin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON30466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30466.